A trial will enroll up to 60,000 participants to assess the safety and efficacy of a COVID-19 vaccine candidate that only requires a single dose. 
 

A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.

Pharmacy Times® interviewed Anne Marie Kondic, PharmD, the executive director of the Community Pharmacy Foundation, on the grant opportunities on the horizon that support the practice of pharmacy in the community setting.

In a comprehensive systematic review that assessed risk factors for HZ infection, researchers found that immunosuppression through HIV/AIDS or malignancy places individuals at a significant risk.

More than half of high-risk patients with resected, stage III BRAF V600-mutated melanoma who were treated with dabrafenib and trametinib were alive and relapse-free at 5 years.

The COVID-19 pandemic will be felt in the oncology space long after the pandemic is over, study shows. 

 

When treating patients with seasonal allergic rhinitis caused by pollens, pharmacists can maintain the same dosage or use a step-down therapy approach as pollen levels fall.

Experts discuss the recommendation in monitoring when using DOACs.

The CheckMate 9ER trial took 2 drugs used as monotherapies in the second line of therapy, nivolumab and cabozantinib, and combined them for use as a first-line treatment against standard of care, sunitinib.

More targeted therapies often have better toxicity profiles, allowing patients to remain adherent for longer.

Pharmacists can deliver medication therapy management services in various settings for individuals with mental health conditions.

Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.